Table 1.
Utilisation of different Interferon Beta formulations
| Avonex® | Betaferon® | Extavia® | Plegridy® | Rebif® | |
|---|---|---|---|---|---|
| Number | 618 | 348 | 69 | 259 | 1220 |
| Age, years | 45.1 ± 13.8 | 48.1 ± 13.2 | 49.7 ± 14.2 | 42.1 ± 17.7 | 41.7 ± 16.0 |
| Sex, females (%) | 425 (68.77%) | 211 (60.63%) | 49 (71.01%) | 178 (68.72%) | 806 (66.06%) |
| Charlson comorbidity index | |||||
| 0 | 301 | 172 | 43 | 107 | 632 |
| 1–2 | 27 | 32 | 8 | 6 | 35 |
| > 2 | 3 | 3 | 1 | 3 | 7 |
Table shows the number of individual treatment periods for different Interferon Beta formulations, along with age, sex distribution (with percentage), and Charlson comorbidity index (for patients with hospital records). The cohort included 2171 individuals, overall resulting into 2514 individual treatments with Interferon Beta